These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27323346)

  • 1. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
    Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
    Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16, HPV, and Cetuximab: What Is the Evidence?
    Bonner JA; Mesia R; Giralt J; Psyrri A; Keilholz U; Rosenthal DI; Beier F; Schulten J; Vermorken JB
    Oncologist; 2017 Jul; 22(7):811-822. PubMed ID: 28526718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
    Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
    Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
    Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
    Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E
    BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
    Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
    J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
    Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
    Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.
    Pajares B; Perez-Villa L; Trigo JM; Toledo MD; Alvarez M; Jimenez B; Medina JA; de Luque V; Jerez JM; Alba E
    Clin Transl Oncol; 2014 Apr; 16(4):418-24. PubMed ID: 24193865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association of HPV infection, p16 status, and efficacy of radiotherapy with or without cetuximab in advanced oropharyngeal squamous cell carcinoma].
    Nieder C
    Strahlenther Onkol; 2016 Dec; 192(12):959-960. PubMed ID: 27757500
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
    Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
    Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Samuels SE; Tao Y; Lyden T; Haxer M; Spector M; Malloy KM; Prince ME; Bradford CR; Worden FP; Schipper M; Eisbruch A
    Oral Oncol; 2016 Mar; 54():68-74. PubMed ID: 26776757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.
    Riaz N; Sherman E; Koutcher L; Shapiro L; Katabi N; Zhang Z; Shi W; Fury M; Wong R; Wolden S; Rao S; Lee N
    Am J Clin Oncol; 2016 Feb; 39(1):27-31. PubMed ID: 24401670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
    Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
    Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.